HKEX: 6990
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
View original source (HKEXnews)Company analysis
Earlier from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
- Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
- Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
- Kelun-Biotech Announces 2026 Interim Results
- NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC